Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Johnson & Johnson's Balversa granted MHRA approval in bladder cancer
J&J's Balversa granted UK marketing authorisation for treating unresectable or metastatic urothelial carcinoma with FGFR3 alterations, after positive THOR trial results showing improved survival and response rates compared to chemotherapy.
MHRA grants approval for bladder cancer drug erdafitinib
UK MHRA approves BALVERSA (erdafitinib) for treating unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations, offering a new option for patients who have undergone at least one line of PD-1 or PD-L1 inhibitor therapy. Erdafitinib, an oral FGFR kinase inhibitor, extends overall survival compared to chemotherapy, with a median survival of 12.1 months versus 7.8 months.
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study
Protagonist Therapeutics to present final Phase 2 REVIVE study data on rusfertide for polycythemia vera at the 66th ASH Annual Meeting in San Diego, December 7-10, 2024.
Conflicting interpretations and FDA reputation: the case of post-market surveillance of breast implants
Conflicting interpretations on breast implant safety highlight FDA's commitment to transparency and stakeholder engagement, despite challenges in post-market surveillance and data quality. The FDA's reputation is both strengthened and challenged by these conflicts, necessitating robust information-gathering mechanisms to manage public health risks and maintain credibility.
EMA accepts Marketing Authorization Application for biosimilar to Simponi
EMA accepts Alvotech and Advanz Pharma’s MAA for AVT05, a biosimilar to J&J’s Simponi for treating chronic inflammatory diseases. AVT05 targets TNF alpha, aiming to reduce costs and increase patient access. Positive clinical results in RA patients support its development, mirroring the global biosimilar market growth.
EMA accepts Alvotech and Advanz Pharma's AVT05 MAA
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA, a biosimilar to J&J’s Simponi, marking the first global MAA filing for a Simponi biosimilar. AVT05 targets chronic inflammatory conditions and is expected to conclude its approval process by Q4 2025.
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune reports Q3 2024 financials: CHF 157.9M cash, JNJ-2056 Fast Track designation, CHF 24.6M milestone payment, and Phase 2 VacSYn trial on track for PD.
Cilta-Cel May Outperform Standard Care for Relapsed, Refractory Myeloma
Ciltacabtagene autoleucel (cilta-cel) may outperform standard-of-care (SOC) regimens for lenalidomide-refractory relapsed/refractory multiple myeloma, according to an indirect comparison. The analysis, presented at the 21st Annual International Myeloma Society Annual Meeting, showed cilta-cel had higher overall response rates, very good partial responses, and complete responses compared to SOC regimens. Benefits were also observed in progression-free survival and time to next treatment.
New Guselkumab Data Indicate Robust Effectiveness in Crohn Disease, Plaque Psoriasis
Guselkumab (Tremfya) demonstrated effectiveness in clearing overlooked plaque psoriasis in SPECTREM trial, achieving optimal IGA scores in 74.2% of patients vs. 12.4% with placebo. In GRAVITI study, guselkumab showed rapid onset of action in Crohn disease, with 56.1% achieving clinical remission vs. 21.4% with placebo. Guselkumab is the first fully human, dual-acting monoclonal antibody approved for ulcerative colitis.
© Copyright 2025. All Rights Reserved by MedPath